LAB vs REGN · rev $174.4M vs P/E 14, rev $14.34B
Standard Biotools Inc (LAB) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LAB currently screens at market cap $317.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LAB and REGN stock pages for the full models.
Not investment advice.